Combination of Cytokine Hemosorption and High-volume Hemofiltration in Acute Pancreatitis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorEfferon JSC
About this trial
Mortality from severe acute pancreatitis reaches 42%. The prognosis of acute pancreatitis is associated with the development of acute inflammatory response syndrome (SIRS) and multiple organ failure (MOF). Due to the lack of etiological therapy, the treatment of acute pancreatitis is predominantly symptomatic.
Severity and mortality are associated with early systemic inflammatory response syndrome (SIRS) and septic complications in the later stages of the disease.
In connection with a pronounced inflammatory reaction ("cytokine storm") in the early phase of endogenous intoxication of acute pancreatitis, a promising therapeutic approach is the extracorporeal removal of cytokines.
This prospective study intends to study the effect of hemoperfusion (Efferon CT) in combination with high-volume hemofiltration (HVHF) on the severity of symptoms of endogenous intoxication and indicators of organ dysfunction in acute pancreatitis.
Eligibility criteria
Qualifiers
Age from 18 to 75 years old,
Acute pancreatitis according to the Atlanta classification of OP (2012), without signs of infection,
Acute pancreatitis confirmed by tomography. Score according to the Modified CTSI Pancreatitis Severity Index: from 4 points and above,
No more than 3 days from the onset of an attack of acute pancreatitis,
Disqualifiers
Age over 75,
More than 3 days from the onset of an attack of acute pancreatitis,
An attack of acute pancreatitis, as an exacerbation of chronic pancreatitis.
Acute pancreatitis as a complication of a surgical operation,
Trial design
Treatments tested in this trial
- Efferon CT
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov